Clinical Trial

Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial

Study acronym: REPOTHYROID-II
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-03-16; most recent amendment 2026-06-17.
Trial Details
NCT Number NCT07485569
Lead Sponsor Radboud University Medical Center
Collaborators: Maastricht University, EU Horizon, Horizon Europe
Conditions Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
Enrollment 10 participants
Start Date 2026-06-01
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-22